50
Participants
Start Date
March 27, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
tirzepatide
Participants will be educated on dietary and lifestyle changes. Participants will self inject 2.5 mg tirzepatide subcutaneously once weekly and maintain a drug administration diary. Dose escalation will proceed per package directions if instructed by study team at follow up visits.
Standard of Care
Participants will be educated on dietary and lifestyle changes
RECRUITING
University of Kentucky, Lexington
Marlene Starr
OTHER